Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients

BackgroundThe European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is the instrument most frequently used to measure quality of life in cancer patients, whereas the EQ-5D is widely used to measure and evaluate general health status. Although the EORTC QLQ-C30 has been mapped to EQ-5D utilities, those studies were limited to patients with a single type of cancer. The present study aimed to develop a mapping relationship between the EORTC QLQ-C30 and EQ-5D-based utility values at the individual level.MethodsThe model was derived using patients with different types of cancer who were receiving chemotherapy. The external validation set comprised outpatients with colon cancer. Ordinary least squares regression was used to estimate the EQ-5D index from the EORTC QLQ-C30 results. The predictability, goodness of fit, and signs of the estimated coefficients of the model were assessed. Predictive ability was determined by calculating the mean absolute error, the estimated proportions with absolute errors > 0.05 and > 0.1, and the root-mean-squared error (RMSE).ResultsA model that included global health, physical, role, emotional functions, and pain was optimal, with a mean absolute error of 0.069 and an RMSE of 0.095 (normalized RMSE, 8.1%). The explanatory power of this model was 51.6%. The mean absolute error was higher for modeled patients in poor health.ConclusionsThis mapping algorithm enabled the EORTC QLQ-C30 to be converted to the EQ-5D utility index to assess cancer patients in Korea.

[1]  John Brazier,et al.  Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? , 2009, Health and quality of life outcomes.

[2]  Andrew Bottomley,et al.  EORTC QLQ-C30 Scoring Manual , 1995 .

[3]  D. Feeny,et al.  Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. , 1996, Medical care.

[4]  M. Versteegh,et al.  Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[5]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[6]  Aki Tsuchiya,et al.  A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures , 2010, The European Journal of Health Economics.

[7]  R. Brooks EuroQol: the current state of play. , 1996, Health policy.

[8]  J. Brazier,et al.  The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.

[9]  M. Boyle,et al.  Multiattribute and Single‐Attribute Utility Functions for the Health Utilities Index Mark 3 System , 2002, Medical care.

[10]  M. van der Pol,et al.  Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[11]  H. Kim,et al.  Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea , 2012, Quality of Life Research.

[12]  M. Jo,et al.  Validity and reliability of the EQ-5D for cancer patients in Korea , 2012, Supportive Care in Cancer.

[13]  Andrew Briggs,et al.  Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences , 2010, The European Journal of Health Economics.

[14]  Hye-young Kang,et al.  Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients , 2012, Quality of Life Research.

[15]  Nick Kontodimopoulos,et al.  Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[17]  Benjamin M Craig,et al.  Deriving a preference-based measure for cancer using the EORTC QLQ-C30. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[18]  Frank de Charro,et al.  The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective , 2003, Springer Netherlands.

[19]  Paul Kind,et al.  South Korean time trade-off values for EQ-5D health states: modeling with observed values for 101 health states. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  R. Deyo,et al.  Generic and Disease-Specific Measures in Assessing Health Status and Quality of Life , 1989, Medical care.

[21]  Desmond Curran,et al.  EORTC QLQ-C30 Scoring Manual (2nd edition) , 1999 .

[22]  Donna Rowen,et al.  Mapping onto Eq-5 D for patients in poor health , 2010, Health and quality of life outcomes.

[23]  D. Heo,et al.  Validation of the Korean version of the EORTC QLQ-C30 , 2004, Quality of Life Research.